Biomarkers of response to therapy in oesophago-gastric cancer

Khaleel Fareed(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Stewart G. Martin(University of Nottingham), Irshad Soomro, Simon L. Parsons(Galapagos (Belgium)), Philip Kaye(Nottingham University Hospitals NHS Trust), Mohammad Ilyas(John Radcliffe Hospital)

Gut

December 17, 2008

10.1136/gut.2008.155861

Cited by 86

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

|New England Journal of Medicine|2010|4.5k

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

|The Lancet|2022|664

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

|The Lancet Oncology|2013|605

Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process

|Gastroenterology|2012|378

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

|The Lancet Oncology|2014|374